Introduction
============

Fibromyalgia (FM) is a common chronic widespread pain condition in which patients typically present with allodynia and hyperalgesia in addition to experiencing many auxiliary symptoms ([Table 1](#t1-ndt-4-1059){ref-type="table"}) ([@b146-ndt-4-1059]; [@b42-ndt-4-1059]; [@b76-ndt-4-1059]). The American College of Rheumatology (ACR) criteria for the classification of FM established in 1990 require a history of widespread pain for at least 3 months and tenderness, determined by a force of 4 kg, in at least 11 of 18 defined tender points ([@b146-ndt-4-1059]). The presence and severity of FM, which is often reliant on the patient's self-reported symptoms, cannot be determined by objective clinical findings, radiographic abnormalities or routinely used laboratory tests ([@b102-ndt-4-1059]; [@b14-ndt-4-1059]). Localized or regional pain in most patients with FM precedes the widespread pain, which could suggest the latter develops from the former. Although pain is often considered the predominant feature, FM is a complex and difficult to treat chronic condition that usually requires a multidisciplinary approach using both pharmacological and non-pharmacological management. Classification and treatment of FM is often further complicated by a waxing and waning course of the symptoms being typical and the presence of co-morbid conditions ([Table 2](#t2-ndt-4-1059){ref-type="table"}).

Many of the symptoms (fatigue, sleep dysfunction, stiffness, depression, anxiety, cognitive disturbance) reported in clinical practice in addition to the pain and tenderness, however, present a condition with a complexity that is probably beyond the ACR 1990 classification ([@b81-ndt-4-1059]). Nevertheless based upon the ACR 1990 criteria, epidemiological studies report prevalence of the condition is 2% to 4% of the general population, increasing to greater than 7% of those over 70 years of age ([@b121-ndt-4-1059]). The patient population consists of a female to male ratio of 9:1, and the most common age group is 45 to 60 years. Related to this, FM has emerged over the past 20 years as a leading cause of visits to rheumatologists, either alone or as an accompaniment of other rheumatic disorders ([@b22-ndt-4-1059]). Although an epidemiological study looks at the incidence, distribution, and control of a particular disease in a population, the outcomes are dependent on the clarity of definition of the condition. The complexity of FM is probably responsible for limited epidemiological data and thereby a likely underestimation where subjects presenting with FM symptoms remain undiagnosed.

A study published in 2003 examined the general health status and work incapacity, and views on the effectiveness of therapy of patients over a two-year observation period ([@b111-ndt-4-1059]). Although there was general satisfaction with quality of life improvement and health status, despite many various treatments received, the patients with FM showed no improvement in pain. The authors suggested that the positive outcomes and satisfaction was probably the result of patient instruction and education of the disease. As a consequence of high prevalence, frequent co-morbidities, and frustration with current treatment modalities, it is increasingly evident that FM represents a significant challenge ([@b73-ndt-4-1059]).

Further, symptom expression in FM tends to vary on an individual basis, indicative of heterogeneity within the condition and the possibility of subgroups of patients with FM. Several studies have suggested heterogeneity in the presentation of FM with differences in biological variables (eg, positive antinuclear antibodies, cytokine abnormalities, growth hormone, thyroid hormones) supportive of subgroups within the patient population ([@b24-ndt-4-1059]; [@b5-ndt-4-1059]; [@b66-ndt-4-1059]; [@b126-ndt-4-1059]; [@b104-ndt-4-1059]). Subgroups based on responses to pharmacological interventions and psychosocial responses have also been demonstrated ([@b140-ndt-4-1059]; [@b122-ndt-4-1059]; [@b147-ndt-4-1059]; [@b87-ndt-4-1059]; [@b89-ndt-4-1059]).

Management issues
=================

The management of FM has been complicated by the lack of a universally accepted pathophysiological mechanism and overlap with symptoms of other health conditions (eg, chronic fatigue syndrome, myofascial pain, systemic lupus). The development of focused and mechanistically based therapeutic options targeting the array of symptoms of FM has been limited. Current management approaches of improving health status in FM use a rehabilitation model, rather than a classic biomedical model, integrating exercise, education (stress management programs, cognitive behavioral therapy (CBT)) and pharmacological treatments ([@b57-ndt-4-1059]). Although recommendations (eg, European League Against Rheumatism (EULAR), American Pain Society (APS)) for FM management have been published ([@b27-ndt-4-1059]; [@b36-ndt-4-1059]), a universally accepted treatment algorhythm or approach is often lacking. A limitation for gaining consensus regarding optimal management of FM is that in the many clinical trials efficacy of the diverse set of treatments has been inconsistent with a large proportion of patients not reporting clinically significant outcomes. The guidelines published by EULAR and APS provide evidence-based considerations related to evaluation and diagnosis of FM, and non-pharmacological and pharmacological therapies ([@b27-ndt-4-1059]; [@b36-ndt-4-1059]). The evidence regarding effectiveness of treatment tended to favor pharmacological studies where double blinding and placebo controls were possible. Management initially is often drug treatment (which may be as a consequence of patient preferences) plus self-management advice to pace activities and follow a regular activity program appropriate to the individual's need ([@b68-ndt-4-1059]; [@b57-ndt-4-1059]).

There has been a rise in the development of new interventions for the treatment of FM and a variety of outcome measures have been used during clinical trials to assess improvement in patients with FM. Partly due to issues related to the classification of FM there often has not been uniform agreement as to which domains or which assessment tools should be utilized ([@b101-ndt-4-1059]). Often assessment of pain is a primary domain of the instrument. FM, however, has an impact on functioning in daily life from the perspective of the patient, although not all pain assessment instruments address these factors. Fatigue in FM is considered by patients to be the second most important domain after pain and may play a role of relative importance in the deterioration of the active state particularly with respect to the long duration of the symptom ([@b101-ndt-4-1059]). Thus, the complexity of this condition may limit in clinical practice the potential of a single instrument covering the diversity of symptoms of FM raising difficulties such as insensitivity or efficacy misinterpretation associated with the multidimensionality ([@b116-ndt-4-1059]).

Treatment options
=================

Evidence supports exercise and education interventions alone and in combination offering benefit for people with FM ([@b27-ndt-4-1059]; [@b29-ndt-4-1059]; [@b36-ndt-4-1059]); however, the content and duration of interventions and outcomes can be unpredictable. Although the number of studies of exercise or behavioral interventions and education has increased in the past decade, comparisons are limited due to a range of factors such as inconsistent outcome measures, assessment tools, small sample size, and high attrition rates ([@b120-ndt-4-1059]). Good outcomes have, however, been reported with a number of forms of relaxation training including electromyography (EMG) biofeedback, heart rate variability (HRV) biofeedback, meditation-based stress reduction, tai-chi, and yoga therapy ([@b52-ndt-4-1059]; [@b68-ndt-4-1059]; [@b70-ndt-4-1059]; [@b57-ndt-4-1059]). CBT provides improvements in pain-related behavior, coping strategies and overall physical function in patients with FM ([@b141-ndt-4-1059]; [@b110-ndt-4-1059]; [@b20-ndt-4-1059]; [@b136-ndt-4-1059]). Although it has been reported that benefit from CBT can be maintained for 6 months, the efficacy of this form of treatment is often found to be inconsistent and, as a single treatment modality, CBT does not offer distinct advantage over programs of education or exercise ([@b141-ndt-4-1059]; [@b82-ndt-4-1059]; [@b20-ndt-4-1059]). Pretreatment patient characteristics are suggested to be important predictors of the response to CBT and thereby beneficial outcomes ([@b139-ndt-4-1059]; [@b136-ndt-4-1059]).

Exercise rehabilitation has recently gained increased acceptance as a component of the symptom management for FM. Modest effects on functional and symptomatic outcomes in patients with FM have been reported with supervised aerobic exercise training such as cycle ergometry, walking, jogging, and water-based activities ([@b77-ndt-4-1059]; [@b94-ndt-4-1059]; [@b29-ndt-4-1059]). These include improvements in measures of cardiovascular fitness, Fibromyalgia Impact Questionnaire (FIQ) subcales of wellbeing and sleep, psychological function, pain-pressure threshold, and participant-rated and physician-rated disease severity ([@b93-ndt-4-1059]; [@b77-ndt-4-1059]; [@b94-ndt-4-1059]; [@b29-ndt-4-1059]). The ability to engage in long, continuous bouts of activity is often limited by the pain associated with FM, therefore alternative systems, such as interval-type training are likely to be more appealing and tolerable for this patient group. In addition, exercises and activities that strengthen the skeletal muscles (eg, stretching) that do not cause undue pain are also important for patients with FM ([@b78-ndt-4-1059]; [@b113-ndt-4-1059]; [@b99-ndt-4-1059]; [@b25-ndt-4-1059]; [@b29-ndt-4-1059]).

Pharmacological therapies
=========================

The pharmacological approach to the management of the condition has often been influenced by the debate of whether FM is a single entity or a collection of symptoms. As a consequence, drug therapy has often focused toward the individual symptoms, particularly pain, with current pharmacological treatments ([Table 3](#t3-ndt-4-1059){ref-type="table"}) remaining largely empiric ([@b87-ndt-4-1059]; [@b89-ndt-4-1059]). The failure of anti-inflammatory medications, such as the non-steroidal anti-inflammatory drugs, naproxen and ibuprofen, and prednisone to be effective treatments of FM supports a lack of underlying peripheral structural damage and inflammatory signs ([@b38-ndt-4-1059]; [@b59-ndt-4-1059]; [@b151-ndt-4-1059]). A sensory abnormality, with alterations in substance P levels, N-methyl-D-aspartate acid (NMDA) receptors and mono-aminergic activity within the central nervous system (CNS) of patients with FM that would be comparable with central sensitization of nociceptive afferent pathways creating a stimulus-independent pain state has been proposed ([@b49-ndt-4-1059]; [@b2-ndt-4-1059]; [@b98-ndt-4-1059]). Clinical trials of opioid agonists as treatments of FM have been limited and often ineffective. The usefulness of opioids in controlling FM pain may be hindered by the suggestion that the opioid systems are maximally activated or a decreased availability of central μ-opioid receptors results in a reduced efficacy in this patient group ([@b17-ndt-4-1059]; [@b69-ndt-4-1059]).

Recent studies have emphasized the global state of the patient as being an important consideration with quality of life outcomes evaluation as an efficacy assessment of pharmacological therapies. This has identified the value of a number of pharmacological targets in the management of FM, in addition to offering insights to aspects of the pathophysiology of the condition.

Bioamine modulators
-------------------

There appears to be a failure in patients with FM to modulate pain due to noxious stimuli because of dysfunction in the descending inhibitory pain pathways ([@b83-ndt-4-1059]; [@b132-ndt-4-1059]; [@b80-ndt-4-1059]). Serotonergic and norepinergic neurons in the descending inhibitory system that links the periaqueductal gray and the rostal ventromedial medulla with the spinal cord are involved in pain regulation ([@b2-ndt-4-1059]). Thus, enhancement of the activity of serotonin and norepinephrine within these structures would be expected to evoke analgesia.

Often antidepressants, particularly tricyclic antidepressants (TCAs) such as amitriptyline and dothiepin, have been first-line pharmacological therapies for FM ([@b14-ndt-4-1059]; [@b87-ndt-4-1059]). Low-dose TCAs have been significantly effective in the management of sleep, pain, and fatigue in patients with FM ([@b33-ndt-4-1059]; [@b34-ndt-4-1059]; [@b119-ndt-4-1059]; [@b117-ndt-4-1059]; [@b16-ndt-4-1059]; [@b102-ndt-4-1059]; [@b61-ndt-4-1059]). Inhibition of the reuptake of serotonin and norepinephrine into the neuronal terminals of the descending tracts by low-dose TCAs has been suggested to be responsible for analgesic effect of these agents in FM. Although clinically applicable improvement in pain (≥30% reduction) with TCAs was observed in randomized controlled trials (RCTs), this was often limited to 25% to 45% of FM patients given these drugs ([@b33-ndt-4-1059], [@b34-ndt-4-1059]; [@b119-ndt-4-1059]). The limited utility of TCAs as treatments of FM has been related to unpredictable responses, adverse effects, and a lack of long-term efficacy evidence.

The evaluation of selective serotonin reuptake inhibitors (SSRIs) in clinical trials with FM patients have shown mixed results ([@b145-ndt-4-1059]; [@b7-ndt-4-1059]; [@b10-ndt-4-1059]; [@b115-ndt-4-1059]). Agents with mixed serotonin and norepinephrine activity (eg, fluoxetine and paroxetine) have demonstrated greater efficacy in the management of FM than SSRIs with higher specificity for serotonin reuptake inhibition (eg, citalopram). The conclusion that agents with higher selective activity are less consistent as treatments of FM is supported by the finding that the combination of fluoxetine and amitriptyline was more effective (reduced pain and FIQ scores, and improved sleep) than either drug alone ([@b60-ndt-4-1059]).

New serotonin and norepinephrine reuptake inhibitors (SNRIs; eg, duloxetine, milnacipran, venlafaxine) have become the focus of recent RCTs ([@b14-ndt-4-1059]; [@b87-ndt-4-1059]). Duloxetine has a balanced inhibitory profile of serotonin and norepinephrine reuptake, while milnacipran, similarly to amitriptyline, preferentially inhibits norepinephrine reuptake, but also exhibits weak NMDA receptor inhibition ([@b129-ndt-4-1059]; [@b131-ndt-4-1059]). Duloxetine significantly improved measures of pain and several measures of quality of life (eg, FIQ, Clinical Global Impressions (CGI), Patient Global Impression (PGI)) in patients with FM, with and without depression ([@b11-ndt-4-1059], [@b12-ndt-4-1059]). The reduction of pain and improved quality of life by duloxetine were independent of the presence of depression suggesting the symptoms of FM are not related to this mood state. Although duloxetine is an effective treatment of FM, this has predominantly been observed in female patients and a 50% decrease or greater in any pain score was only achieved in up to 41% (dependent on the treatment regime) of subjects ([@b11-ndt-4-1059], [@b12-ndt-4-1059]). During 6 months of treatment, duloxetine demonstrated durability with outcomes superior to placebo in the improvement of pain and secondary measures such as FIQ, CGI, and Short Form 36 (SF-36) scores ([@b124-ndt-4-1059]). Although fatigue is a common symptom reported by patients with FM ([@b101-ndt-4-1059]), duloxetine failed to improve general or physical fatigue during the course of the trial. Interestingly though, a significant improvement was obtained in the mental fatigue domain suggesting that duloxetine treatment could improve the cognitive dysfunction associated with FM ([@b124-ndt-4-1059]).

Milnacipran relieves pain symptoms and improves measures of quality of life (eg, PGI and FIQ scores) associated with FM ([@b143-ndt-4-1059]; [@b56-ndt-4-1059]). A reduction of pain by 50% or greater was observed in up to 37% of the patient population and a greater improvement in pain reduction was recorded in non-depressed subjects treated with milnacipran. These findings are consistent with the analgesic effects of milnacipran, like those of duloxetine, not being as a consequence of improvement of mood. The durable efficacy of milnacipran as a treatment of FM has been demonstrated in 15-week, 6-month, and 12-month RCTs where multidimensional symptom improvement was reported ([@b40-ndt-4-1059], [@b41-ndt-4-1059]; [@b58-ndt-4-1059]).

The SNRIs, duloxetine and milnacipran, are well tolerated because they do not interact with adrenergic, cholinergic, or histaminergic receptors, or sodium channels and thereby lack many of the adverse effects of TCAs. It is of note, however, that insomnia was a frequently reported adverse effect for duloxetine in a condition that presents sleep dysfunction as a major symptom ([@b11-ndt-4-1059], [@b12-ndt-4-1059]; [@b124-ndt-4-1059]).

Therefore, agents that modulate serotonin and norepinephrine are effective treatments for some, but not all, patients with FM. Although SNRIs are well tolerated, the observation that a significant number of patients do not gain benefit from this treatment can question the relationship of this mechanism of action and the pathophysiology of FM. A critical issue that could be addressed by other SNRIs would be the balance of the norepinephrine versus serotonin reuptake inhibition. Although modulation of serotonin and norepinephrine levels is the primary mechanism of TCAs, SSRIs, and SNRIs, these agents act on multiple nociceptive targets (eg, NMDA receptors, potassium channels) at central and peripheral locations, the contribution of which to the clinical outcomes obtained is unknown ([@b86-ndt-4-1059]; [@b105-ndt-4-1059]). The NMDA receptor antagonists ketamine and dextromethorphan have demonstrated efficacy (pain score) as analgesics in the treatment of FM ([@b39-ndt-4-1059]; [@b62-ndt-4-1059]; [@b45-ndt-4-1059]). Due to a lack of specificity and thereby associated adverse effects, however, NMDA receptor antagonists are not widely accepted as treatments of chronic pain. Interestingly potassium channels, whose functional state has been studied in patients with fibromyalgia, are molecular targets for the management of pain ([@b88-ndt-4-1059]; [@b85-ndt-4-1059]). These molecules have been developed to act optimally at sites related to the bioamine systems and not at the auxillary targets, which could account for the lack of universal effectiveness in this patient population.

It is interesting to note that a reduction in pain and an improvement in health-related quality of life in patients with FM have been demonstrated with tramadol alone, or in combination with acetaminophen ([@b23-ndt-4-1059]). The pharmacological properties of tramadol, which is included in both the EULAR and APS guidelines for FM management, are a mixture of serotonin and norepinephrine reuptake inhibition and weak μ-opioid receptor agonism ([@b53-ndt-4-1059]). The contribution of each of these mechanisms to the outcomes obtained with tramadol is unknown.

In addition to norepinephrine and serotonin, dopamine plays a role in the descending inhibitory pain pathways at the supraspinal level of the thalamus, basal ganglia, and limbic cortex ([@b130-ndt-4-1059]; [@b37-ndt-4-1059]; [@b28-ndt-4-1059]; [@b90-ndt-4-1059]). An abnormal dopamine response to pain in patients with FM, which may be related to prolonged stress, has been reported ([@b149-ndt-4-1059]). A disruption of dopaminergic neurotransmission being involved in the pathophysiology of FM has been further proposed due to a reduction of presynaptic dopamine metabolism, demonstrated by positron emission tomography, in these patients ([@b148-ndt-4-1059]). In one RCT, the dopamine D3/D2 receptor agonist pramipexole reduced pain and improved fatigue and overall function as indicated by the FIQ score in patients with FM with no withdrawals from the study because of adverse effects ([@b74-ndt-4-1059]). However, as observed with other pharmacological treatments, pramipexole failed to evoke 50% or greater decrease in pain in all patients involved in the clinical trial with this efficacy level only being achieved in 42% of subjects. The patients in this trial, however, were taking their current medication, which included opioid analgesics, making the study outcomes difficult to interpret. Ropinirole, another dopamine D3/D2 receptor agonist, failed to achieve a significant therapeutic response in patients with FM ([@b75-ndt-4-1059]); whether the lack of efficacy of ropinirole is independent of dopamine receptor modulation remains to be established.

Alpha2-delta ligands
--------------------

The release of neurotransmitters that play a role in pain processing, such as glutamate and substance P, is regulated by calcium influx into nerve terminals within the nociceptive pathways ([@b106-ndt-4-1059]; [@b50-ndt-4-1059]). Block of the presynaptic calcium channels by ligands of the α~2~δ subunit of that channel (eg, gabapentin, pregabalin) will decrease the neurotransmitter release and attenuate abnormal hyperexcitability of neuronal networks such as that associated with chronic pain. Functionally, α~2~δ-subunit ligands exhibit use-dependent properties giving these drugs a significant clinical advantage in that they will be expected to significantly modulate pathological functions related to maintained depolarization or hyperexcitability, but only minimally alter physiological synaptic function ([@b50-ndt-4-1059]).

In patients with FM, gabapentin improved pain, FIQ, CGI, and PGI scores and sleep quality, however with a high incidence of adverse effects (eg, sedation, dizziness) ([@b9-ndt-4-1059]). Although a 30% or greater reduction in pain score was only achieved in 51% of gabapentin-treated patients, these findings support this concept as a therapeutic approach to FM. Pregabalin significantly reduced the pain score and improved sleep and fatigue in RCTs (of 8, 13, and 14 weeks) involving patients with FM, demonstrating efficacy against the three major symptoms of the condition ([@b47-ndt-4-1059]; [@b13-ndt-4-1059]; [@b103-ndt-4-1059]). Although pregabalin monotherapy provides benefit in the management of FM as demonstrated by significantly more patients gaining 50% or greater improvement in pain with drug treatment than placebo treatment, this level of benefit was in a limited (up to 30%) number of subjects. The number of pregabalin responders only increased up to 50% of the subjects when an efficacy level of 30% or greater decrease in pain scores was determined. Further, little additional benefit, with an increase in the incidence of adverse effects, was conferred by the highest dose (600 mg/day) of pregabalin studied relative to that gained with the lower doses (300 and 450 mg/day) suggesting that in pregabalin-responders an efficacy ceiling was met ([@b47-ndt-4-1059]; [@b13-ndt-4-1059]; [@b103-ndt-4-1059]).

The durability of the effects of pregabalin on pain, fatigue, and sleep disturbance was demonstrated in a 6-month, double-blind, placebo-controlled trial, with an onset of beneficial effects within 1 week of treatment ([@b46-ndt-4-1059]). The durability of the treatment was determined by the time to loss of therapeutic response in patients who had previously demonstrated improvement in FM symptoms with pregabalin. At the end of the trial, 68% of drug-treated patients compared to 39% of placebo-treated patients maintained therapeutic response related to improvement in pain, sleep, fatigue, and functional status. Although more pregabalin- than placebo-treated patients discontinued due to adverse effects, pregabalin was well tolerated ([@b46-ndt-4-1059]). Pregabalin has recently been approved by the FDA for the treatment of FM.

Hypnotics
---------

Sedative hypnotics that modulate benzodiazepine receptors receptor complex (BZD1 and BZD2) located on the GABA~A~ have been evaluated in patients with FM ([@b14-ndt-4-1059]; [@b87-ndt-4-1059]; [@b121-ndt-4-1059]). The benzodiazepines, temazepam, alprazolam, and bromazepam, which act non-selectively at BZD receptors, have given inconsistent results in clinical trials in patients with FM. Although temazepam improved sleep quality, no concomitant improvement in pain or fatigue symptoms was observed ([@b71-ndt-4-1059]). Thus, a symptomatic benefit outcome was evoked by modulation of BZD receptors by benzodiazepines rather than management of the condition. Although benzodiazepines are useful in conditions involving neuronal hyperexcitability (eg, epilepsy, spasticity) and would be assumed to have the potential of controlling the pain related to the enhanced general sensitization in FM, acceptable efficacy has not been observed. Zolpidem and zopiclone, short-acting non-benzodiazepine hypnotics which interact preferentially with the BZD1 receptor, also improved sleep in patients with FM, but again failed to improve pain ([@b51-ndt-4-1059]; [@b63-ndt-4-1059]; [@b108-ndt-4-1059]). The failure of modulators of processes within the GABAergic inhibitory neurons to provide suppression of the symptoms of FM could suggest that the pathophysiology does not involve a state of hyperexcitability, but is related to an altered threshold of neuronal activation.

Sodium oxybate, the sodium salt of gamma-hydroxybutyrate (GHB), provided significant improvements in the major symptoms of FM (ie, pain, tenderness, sleep quality, and fatigue), which have been largely attributed to its capacity to consolidate and improve deep sleep ([@b123-ndt-4-1059]; [@b150-ndt-4-1059]). The improvement in pain, at least, being related to improved sleep is supported by the outcome of a significant correlation (r = 0.55, p \< 0.001) between changes in the pain scale and improvements in sleep quality. The specific processes responsible for the sleep disruption in FM are unclear. Sleep impacts on pain, fatigue, and social functioning ([@b128-ndt-4-1059]; [@b134-ndt-4-1059]); nevertheless, it is not clear whether sleep disturbance is a symptom occurring itself or as a co-morbidity. It has been suggested that the relationship between pain and sleep may be bidirectional such that pain might increase sleep disturbance and disturbed sleep could intensify pain ([@b4-ndt-4-1059]). Whether the pathophysiology for one symptom is responsible for the initiation of another symptom, or a single mechanism is concomitantly responsible for more than one symptom still requires determination. GHB is a precursor to GABA and exhibits agonist receptor and a postulated GHB-specific activity at the GABA~B~ receptor ([@b92-ndt-4-1059]). Data are awaited as to which, if any, is the primary mechanism responsible for the effectiveness and thereby beneficial outcomes with sodium oxybate in the management of FM ([@b107-ndt-4-1059]).

Pathophysiology
===============

A number of hypotheses have been proposed regarding the pathophysiology of FM, which includes a dysfunction of pain modulatory systems within the CNS, neuroendocrine dysfunction, and dysautonomia ([@b127-ndt-4-1059]; [@b2-ndt-4-1059]; [@b8-ndt-4-1059]; [@b133-ndt-4-1059]). FM is often described as a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, although lacking signs of underlying peripheral structural damage and inflammation. A cyclic model of the potential interrelationship of the proposed pathophysiological processes and the primary symptoms associated with FM is presented in [Figure 1](#f1-ndt-4-1059){ref-type="fig"}. Altered processing within the central nociceptive system is often proposed to be central to the manifestation of the condition and the typically experienced symptoms. As a consequence, pain has been described as both a symptom and a contributor of other symptoms such as fatigue, impairment of concentration, negative mood, degraded sleep, and diminished overall activity (Tuck and Dworkin 2004). Nevertheless, the nociceptive system is possibly one component of a complex network of physiological aspects that express a level of interdependence creating the clinical profile of FM. The cause of the interference in pain processing remains unclear, although involvement of chronic psychological stressors, peripheral pain generators, and inflammatory mediators has been proposed ([@b21-ndt-4-1059]; [@b2-ndt-4-1059]).

Initiation of altered functioning of the nociceptive system has been related to a physical insult, leading to traumatized tissue and localized pain, or a psychological insult, such as stress ([Figure 1](#f1-ndt-4-1059){ref-type="fig"}) ([@b1-ndt-4-1059]; [@b31-ndt-4-1059]; [@b5-ndt-4-1059];Tishler et al 2006). Sensitization of the central nociceptive system occurs due to such a sensory input. Central sensitization implies spontaneous nerve activity, expanded receptive fields, and abnormal temporal summation (or 'wind-up') within the spinal cord. NMDA receptors, found at the postsynaptic membrane in the dorsal horn of the spinal cord, are proposed to play a role in these phenomena. Once central (sensitization) hyperexcitability has been established, subsequent responses to normal stimuli are exaggerated and the threshold for the activation of new inputs is reduced. Central to a variety of neuronal processes, including synaptic plasticity and neurotoxicity, is the activation of NMDA receptors by glutamate leading to a rise in intracellular calcium and the initiation of second messenger pathways that mediate long-term potentiation (enduring enhancement of synaptic transmission after the initiating stimulus has ceased) ([@b91-ndt-4-1059]; [@b137-ndt-4-1059]; [@b118-ndt-4-1059]). In addition, nitric oxide production by neuronal nitric oxide synthase is induced by the calcium influx, which is believed to evoke a retrograde signaling action enhancing presynaptic glutamate release ([@b48-ndt-4-1059]). Studies on levels of nitric oxide in FM, however, have not been conclusive ([@b114-ndt-4-1059]). Similarly substance P, a peptide neurotransmitter associated with pain transmission, in addition to many other actions enhances the responsiveness of NMDA receptors to glutamate ([@b48-ndt-4-1059]). Although elevated levels of substance P in the cerebrospinal fluid of patients with FM have been reported ([@b142-ndt-4-1059]; [@b125-ndt-4-1059]), such observations have not been confirmed in other studies. In patients with fibromyalgia temporal summation of nociceptive stimuli (where the intensity of rapidly repeated noxious stimuli is perceived to increase) is enhanced and diffuse noxious inhibitory control is reduced ([@b84-ndt-4-1059]; [@b132-ndt-4-1059]; [@b80-ndt-4-1059]).

Studies utilizing neuroimaging techniques such as functional magnetic resonance imaging (fMRI), and single photon emission computed tomography (SPECT) have demonstrated that patients with FM exhibit neural activity in regions involved in processing the sensory pain sensation, in response to the administration of a noxious pressure or heat stimulus, that differs from that observed in health controls ([@b144-ndt-4-1059]; [@b65-ndt-4-1059]). Although both patients with FM and healthy controls detect and experience a full range of perceived pain stimuli, the stimulus intensity threshold of the former group is significantly lower. The status of neural activity in the patients with FM was related to physiological and not psychological stimuli as mood states, such as depression, did not appear to influence the outcome. Data from SPECT neuroimaging studies have also been predictive of therapeutic responsiveness of treatment of patients with FM with amitriptyline and ketamine ([@b3-ndt-4-1059]; [@b64-ndt-4-1059]). It is important to recognize that such neuroimaging techniques do not measure neural activity directly, but infer activity from localized changes in regional cerebral blood flow occurring in response to neural metabolic demand. Further work is required to determine whether these observations are related to neural demand influencing vascular status or whether a compromised vasculature, due to dysautonomia, is impacting on neural activity, or a combination of both. Neuroimaging has focused on the pain dimension of FM, where other symptoms such as fatigue and disturbed sleep have a significant role, as do non-noxious stimuli such as auditory and tactile ([@b55-ndt-4-1059]).

The intensity and duration of the insult, and thereby pain, required to achieve the level of sensitization related to FM is not understood. Data from genetic studies could indicate a familial predisposition in vulnerable subjects to the development of FM ([@b32-ndt-4-1059]). Although the frequency of polymorphisms of the serotonin transporter promoter gene, 5-HT2A receptor gene, catechol-O-methyltransferase gene, and dopamine D4 receptor gene is changed in patients with FM, the relevance to the etiology and pathophysiology is unknown ([@b26-ndt-4-1059]; [@b112-ndt-4-1059]; [@b43-ndt-4-1059]; [@b67-ndt-4-1059]; [@b30-ndt-4-1059]). Consequently what would be an innocuous event in the majority of the people has a marked outcome in 2%--4% of the population.

In addition to increasing the sensitivity of the central nociceptive system the sensory inputs appear to lead to activation of circuits of the limbic system such as the autonomic nervous system and the neuroendocrine hypothalamic pituitary adrenal (HPA) axis ([Figure 1](#f1-ndt-4-1059){ref-type="fig"}). HPA axis dysfunction in patients with FM is characterized by elevated cortisol levels lacking diurnal fluctuation with blunted secretion in response to stress ([@b2-ndt-4-1059]; [@b133-ndt-4-1059]). This is consistent with the HPA axis being underactivated to stimuli and some patients with FM exhibiting a subnormal adrenocortical function. There are no structural abnormalities in the endocrine glands of the HPA axis and current data do not allow an explanation of the location of the defect of the HPA dysfunction. Dysautonomia has also been suggested to be responsible for the generation and maintenance of the symptoms of FM ([@b98-ndt-4-1059]). Selective sympathetic blockade with guanethidine in patients with FM leads to a reduction in pain and number of tender points with restoration of the symptoms by norepinephrine injections ([@b15-ndt-4-1059]; [@b97-ndt-4-1059]). An increased sympathetic and decreased parasympathetic activity in patients with FM resulting in a persistently hyperactive sympathetic nervous system that is hyporeactive in response to stress has been reported ([@b95-ndt-4-1059]; [@b96-ndt-4-1059]; [@b44-ndt-4-1059]). Chronic hyperstimulation of the α-adrenergic receptors of the sympathetic nervous system could lead to receptor desensitization and downregulation. The augmented sympathetic activity appears to be greater in women than men, suggesting that women with FM may have more severe autonomic dysfunction. Although TCAs and SNRIs, through modulation of bioamine levels, may achieve benefit in the treatment of FM by an effect on descending pain pathways, the lack of tolerance or efficacy of these drugs may be associated with an augmentation of the sympathetic component of the dysautonomia.

FM patients demonstrate significant variability in stress reactivity and the different response patterns related to potential autonomic response specificity ([@b139-ndt-4-1059]; [@b135-ndt-4-1059]). The activation of the processes related to the limbic circuits in patients with FM appears to express an increased sensitivity to stressors perhaps due to the altered functioning preventing a normal physiological regulation of such an event and thereby exacerbation of certain systems. For example the limbic system, HPA axis, and autonomic nervous system activation could be related to mood arousal resulting in altered sleep architecture and enhanced anxiety leading to depression. Such outcomes within the limbic system may also be related to the memory and cognitive function, and mental fatigue (fibrofog) in patients with FM ([@b57-ndt-4-1059]). The blunted sympathetic activity to stress and impaired parasympathetic modulation of the dysautonomia may also be associated with the prevalence of symptoms such as syncope, morning stiffness, pseudo-Raynaud's phenomenon, and intestinal irritability observed in this patient population ([@b127-ndt-4-1059]; [@b98-ndt-4-1059]).

Stress has central hyperalgesic effects that could be due to a direct central nociceptive system or an indirect peripheral action. The enhanced peripheral sympathetic nervous system tone related to the dysautonomia will, for example, lead to generalized widespread peripheral vasoconstriction (in addition to other autonomic responses). As a consequence of an associated reduced blood flow, a relatively mild challenge (eg, stretching, light exercise) to the skeletal muscle can evoke a state of ischemia and changed muscle energy metabolism. Low levels of phosphocreatine and ATP at rest, low phosphorylation potential, and total oxidative capacity, and a reduced number and size of mitochondria in skeletal muscle of patients with FM have been identified ([@b19-ndt-4-1059]; [@b18-ndt-4-1059]; [@b79-ndt-4-1059]; [@b100-ndt-4-1059]). Such a vascular event would cause the sensitization of ergoreceptors, with the potential outcome of muscle fatigue, and the sensitization or activation of nociceptors leading to multifocal muscular pain and hyperalgesia well beyond the area of the initial physical insult. The generalized sensitization to pain within skeletal muscle will be associated with spatially distributed allodynia and hyperalgesia (tender points). Therefore, changes in peripheral factors, especially in intramuscular microcirculation and in muscle energy metabolism, could act as excitatory triggers for the alterations in the nociceptive system in the CNS and for multifocal pain in the muscles ([@b72-ndt-4-1059]; [@b2-ndt-4-1059]). The activation of the nociceptors leading to further activation of the central nociceptive system will complete a loop within the processes related to the pathophysiological mechanisms of FM ([Figure 1](#f1-ndt-4-1059){ref-type="fig"}).

The potential of development of cyclic processes enables a trigger (eg, tender points, tissue trauma, exercise, stress) at any point within the loop to initiate and express (to varying degrees) the array of symptoms typical of FM. Evidence suggests patients with FM exhibit greater sensitivity to a range of sensory stimuli including auditory, tactile, heat, and pressure ([@b54-ndt-4-1059]; [@b35-ndt-4-1059]; [@b109-ndt-4-1059]; [@b55-ndt-4-1059]). The heightened responsiveness to sensory stimulation may be related to a lack of inhibitory control over repetitive or irrelevant somatosensory stimulation ([@b54-ndt-4-1059]; [@b35-ndt-4-1059]; [@b109-ndt-4-1059]; [@b55-ndt-4-1059]). These findings are consistent with FM being in part due to a global disturbance in sensory processing rather than an isolated abnormality in pain processing.

Conclusion
==========

FM is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological interventions. It is described as a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, where the pathophysiology could include dysfunction of the CNS pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. Current data do not allow an understanding of the exact locations of the defects in these systems. In addition, whether aspects of the proposed pathophysiology are causal or consequential requires clarification. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM.

Although a variety of treatment modalities have been utilized in the management of FM, an effective (\>50% of the patient population gaining benefit) means of therapy is still awaited. Treatments have demonstrated an improvement in health status in a proportion of patients with FM in clinical trials; however, these findings require confirmation in usual-care settings of the subjects. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have now been identified that demonstrate a multidimensional efficacy in this condition. The large percentage of patients who are refractory to these treatments during RCTs, makes it difficult to determine the relationship of the primary mechanism of action of the drugs to the pathophysiology of FM. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies. Finally, the diversity of the biology related to FM and the variability in responsiveness to treatments is consistent with the existence of subgroups of patients with potentially differing pathophysiology.
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###### 

Symptoms of fibromyalgia

  ----------------------------
  Widespread pain
  Hyperalgesia and allodynia
  Chronic fatigue
  Sleep disturbance
  Stiffness
  Depression
  Paresthesias
  Cognitive disruption
  Exercise intolerance
  ----------------------------

###### 

Examples of conditions frequently co-morbid with fibromyalgia

  ----------------------------------
  Chronic low back pain
  Irritable bowel syndrome
  Depression/anxiety
  Temporomandibular joint disorder
  Chronic fatigue syndrome
  Multiple chemical sensitivities
  Interstitial cystitis
  Rheumatoid arthritis
  ----------------------------------

###### 

Examples of current pharmacological treatments of fibromyalgia

  -------------------------------------------------------
  Tricyclic antidepressants (TCAs)
   amitriptyline
   doxepin
  Serotonin-norepinephrine re-uptake inhibitors (SNRIs)
   duloxetine
   milnacipran
   venlafaxine
  Selective serotonin re-uptake inhibitors (SSRIs)
   fluoxetine
   citalopram
  Dopamine agonist
   pramipexole
  Anti-epileptics
   pregabalin
   gabapentin
  Sedative hypnotics
   zopiclone
   zolpidem
  Analgesics
   dihydrocodeine
   morphine
   tramadol
   acetaminophen
  -------------------------------------------------------
